## Background: We retrospectively compared sleeve lobectomy (SL) and pneumonectomy (PN) for lung cancer in terms of surgical complications and postoperative disease-free survival, as well as incidence and pattern of recurrent disease. Methods: From 1977 to 1993, 29 patients with primary lung cance
Comparison of pleuropneumonectomy and limited surgery for lung cancer with pleural dissemination
โ Scribed by Shimizu, Junzo; Oda, Makoto; Morita, Katsuya; Hayashi, Yoshinobu; Arano, Yoshihiko; Matsumoto, Isao; Kobayashi, Koichiro; Nonomura, Akitaka; Watanabe, Yoh
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 448 KB
- Volume
- 61
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
โฆ Synopsis
The role of surgery in the management of lung cancer with pleural dissemination is controversial. We performed a retrospective analysis of our patients with lung cancer and pleural dissemination who were treated surgically. Between 1973 and 1993, 1,206 patients with lung cancer underwent pulmonary resection at Kanazawa University Hospital. Among them, 40 (3.3%) had pleural dissemination without pleural effusion. The 1-, 3-, and 5-year survival rates for 38 patients (except 2 patients undergoing exploratory thoracotomy alone) were 5 1.5%, 19.4%, and 19.4%, respectively. The 1-year survival rate in the 10 patients who underwent pleuropneumonectomy was only 20%, and 9 of these patients died within 18 months postoperatively (1 patient has survived for 25 months). In contrast, the 1-, 3-, and 5-year survival rates for the 14 patients who underwent resection of the primary tumor plus parietal pleurectomy were 85.1 %, 35.5%, and 35.5%, respectively, a significantly better outcome ( P <= 0.01). Seven patients are still alive (the longest survival time is 65 months with the disease). The average survival time in the seven fatal cases was 18 months. In patients with lung cancer accompanied by pleural dissemination, it is quite possible that local excision plus pleurectomy will be justified.
๐ SIMILAR VOLUMES
of surgery in 620 patients with nonsmall cell lung carcinoma (NSCLC) by a genetic algorithm neural network (GANN) using Bayes' theorem compared with logistic 1 Department of Geriatric Medicine, Clinical Sciregression, and the predictive value of tumor volume measures in addition to ences Building, H
## BACKGROUND. Gemcitabine has shown activity in patients with less chemosensitive solid tumors. Phase II screening of novel drugs is an accepted method with which to investigate new therapies in malignant mesothelioma. The European Organization for Research and Treatment of Cancer-Lung Cancer Coo